MAPT and Alzheimer disease: Furthermore, integrating multiomics-based biomarkers, including metabolites, lipids, cholesterol biosynthesis, purine metabolism, lipoproteins, bile acids, and genetics, along with their relationship to pathological amyloid and tau networks, could improve the sensitivity of AD diagnosis.